758 related articles for article (PubMed ID: 31511012)
1. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
[TBL] [Abstract][Full Text] [Related]
3. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
4. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
5. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
6. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
7. Skeletal muscle mass as a predictor of the response to neo-adjuvant chemotherapy in locally advanced esophageal cancer.
Ota T; Ishikawa T; Endo Y; Matsumura S; Yoshida J; Yasuda T; Okayama T; Inoue K; Dohi O; Yoshida N; Sakamoto N; Kamada K; Uchiyama K; Takagi T; Konishi H; Konishi H; Shiozaki A; Fujiwara H; Kishimoto M; Naito Y; Itoh Y
Med Oncol; 2019 Jan; 36(2):15. PubMed ID: 30600347
[TBL] [Abstract][Full Text] [Related]
8. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
[TBL] [Abstract][Full Text] [Related]
10. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia/Muscle Mass is not a Prognostic Factor for Short- and Long-Term Outcome After Esophagectomy for Cancer.
Grotenhuis BA; Shapiro J; van Adrichem S; de Vries M; Koek M; Wijnhoven BP; van Lanschot JJ
World J Surg; 2016 Nov; 40(11):2698-2704. PubMed ID: 27272482
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer.
Mallet R; Modzelewski R; Lequesne J; Mihailescu S; Decazes P; Auvray H; Benyoucef A; Di Fiore F; Vera P; Dubray B; Thureau S
Radiat Oncol; 2020 May; 15(1):116. PubMed ID: 32443967
[TBL] [Abstract][Full Text] [Related]
13. Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.
Anandavadivelan P; Brismar TB; Nilsson M; Johar AM; Martin L
Clin Nutr; 2016 Jun; 35(3):724-30. PubMed ID: 26065721
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy.
Takeda Y; Akiyoshi T; Matsueda K; Fukuoka H; Ogura A; Miki H; Hiyoshi Y; Nagasaki T; Konishi T; Fujimoto Y; Fukunaga Y; Ueno M
PLoS One; 2018; 13(4):e0195406. PubMed ID: 29630652
[TBL] [Abstract][Full Text] [Related]
15. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
16. Skeletal Muscle Loss After Esophagectomy Is an Independent Risk Factor for Patients with Esophageal Cancer.
Nakashima Y; Saeki H; Hu Q; Tsuda Y; Zaitsu Y; Hisamatsu Y; Ando K; Kimura Y; Oki E; Mori M
Ann Surg Oncol; 2020 Feb; 27(2):492-498. PubMed ID: 31549319
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
[TBL] [Abstract][Full Text] [Related]
18. Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer.
Macedo FI; Mesquita-Neto JW; Kelly KN; Azab B; Yakoub D; Merchant NB; Livingstone AS; Franceschi D
Ann Surg Oncol; 2020 Mar; 27(3):662-670. PubMed ID: 31788752
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle loss in the postoperative acute phase after esophageal cancer surgery as a new prognostic factor.
Maeda N; Shirakawa Y; Tanabe S; Sakurama K; Noma K; Fujiwara T
World J Surg Oncol; 2020 Jun; 18(1):143. PubMed ID: 32591002
[TBL] [Abstract][Full Text] [Related]
20. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
